These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1956499)

  • 1. Citric acid in calcium effervescent tablets may favour aluminium intoxication.
    Dorhout Mees EJ; Basçi A
    Nephron; 1991; 59(2):322. PubMed ID: 1956499
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient.
    Main J; Ward MK
    BMJ; 1992 Jun; 304(6843):1686. PubMed ID: 1633526
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute aluminemic encephalopathy in chronic renal failure: the citrate factor.
    Bakir AA
    Int J Artif Organs; 1989 Dec; 12(12):741-3. PubMed ID: 2613353
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperaluminaemia associated with oral citrate and aluminium hydroxide.
    Kirschbaum BB; Schoolwerth AC
    Hum Toxicol; 1989 Jan; 8(1):45-7. PubMed ID: 2714810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function.
    Lin JL; Leu ML
    Nephrol Dial Transplant; 1996 Sep; 11(9):1891-3. PubMed ID: 8918652
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminium concentrations in the brain and bone of rats fed citric acid, aluminium citrate or aluminium hydroxide.
    Slanina P; Falkeborn Y; Frech W; Cedergren A
    Food Chem Toxicol; 1984 May; 22(5):391-7. PubMed ID: 6539288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers.
    Priest ND; Talbot RJ; Austin JG; Day JP; King SJ; Fifield K; Cresswell RG
    Biometals; 1996 Jul; 9(3):221-8. PubMed ID: 8696074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal absorption of aluminium from single doses of aluminium containing antacids in man.
    Weberg R; Berstad A
    Eur J Clin Invest; 1986 Oct; 16(5):428-32. PubMed ID: 3100311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids.
    Kirschbaum BB; Schoolwerth AC
    Am J Med Sci; 1989 Jan; 297(1):9-11. PubMed ID: 2913801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Kanagawa S; Yosikawa Y; Dohi Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of some dietary constituents on aluminum absorption and retention in rats.
    Domingo JL; Gomez M; Llobet JM; Corbella J
    Kidney Int; 1991 Apr; 39(4):598-601. PubMed ID: 2051716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
    Schiessl JH; Schweigart U; Bottermann P; Kopp KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption.
    Nolan CR; Califano JR; Butzin CA
    Kidney Int; 1990 Nov; 38(5):937-41. PubMed ID: 2266679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aluminum-citrate interaction in end-stage renal disease.
    Rudy D; Sica DA; Comstock T; Davis J; Savory J; Schoolwerth AC
    Int J Artif Organs; 1991 Oct; 14(10):625-9. PubMed ID: 1748529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients.
    Nestel AW; Meyers AM; Paiker J; Rollin HB
    Nephron; 1994; 68(2):197-201. PubMed ID: 7830856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 20. The fatal interplay of aluminum and citrate in chronic renal failure: a lesson from three decades ago.
    Bakir AA
    Artif Organs; 2015 Feb; 39(2):87-9. PubMed ID: 25683287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.